-
Former world champion Kiwi surf lifesaver banned for trafficking performance-enhancing drugs
23 May 2025 04:18 GMT
The ruling said the substances - a mixture of peptides, substances that increase growth hormone secretion and experimental substances - are banned in sport at all times.
Foster admitted to breaching anti-doping rule, saying he had purchased the substances …
-
Will Moving Drug Production to the United States Help or Hurt Patients?
25 Apr 2025 17:41 GMT
… regarding the availability of specialty medicines for US patients; making … found below.
Note: The FDA approved the company’s supplemental … the F8 formulation of tesamorelin for injection on March 25 … the availability of specialty medicines for US patients—as …
-
The Future of Specialty Medicine
24 Apr 2025 19:43 GMT
… regarding the availability of specialty medicines for US patients; making … found below.
Note: The FDA approved the company’s … the F8 formulation of tesamorelin for injection on March 25 … why many companies, especially biotechs, may actually be vulnerable …
-
Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA
08 Apr 2025 11:00 GMT
… the U.S. Food and Drug Administration (FDA) has approved the Company … SV® (tesamorelin for injection). Tesamorelin for injection is the only treatment approved in … side effects of prescription drugs to the FDA. Visit http:/…
-
Clinical Insights on HIV-Associated Visceral Fat Following FDA Approval of Tesamorelin F8
26 Mar 2025 13:48 GMT
… , MD, professor of medicine in the Division of … was skinny because the medicines also wasted subcutaneous fat. … differs from general adiposity treatment strategies. "Diet … . Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to …
-
FDA Approves F8 Formulation of Theratechnologies' Tesamorelin for HIV-Associated Lipodystrophy
25 Mar 2025 23:48 GMT
… (sBLA) for EGRIFTA WR (Tesamorelin F8), a treatment for excess visceral abdominal … , senior vice president and chief medical officer at Theratechnologies, he said … Complete Response Letter (CRL). The FDA concluded that the updated formulation …
-
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
25 Mar 2025 21:45 GMT
… U.S. Food and Drug Administration (FDA) has approved the … WR™. Tesamorelin for injection is the only medication approved in … conveniently dosed formulation of tesamorelin is a welcome advancement.” … ;benefit of continuation of treatment in patients who have …
-
FDA Action Alert: GSK, Alnylam, Sanofi and More
10 Mar 2025 21:08 GMT
… FDA decisions this month is for Alnylam Pharmaceuticals, … FDA’s concerns and provided additional data regarding tesamorelin’s immunogenicity risk.
Tesamorelin … biotech is developing for the treatment of paroxysmal supraventricular tachycardia (PSVT). The FDA …
-
Rising HIV Prevalence Fuels Growth In The Industry: Transforming The Egrifta (Tesamorelin Acetate) Market In 2025
05 Mar 2025 12:25 GMT
… of treatments into comprehensive healthcare plans.
o Expansion of personalized medicine strategies … Drug Administration (FDA).
How is the Egrifta Tesamorelin Acetate Market Segmented?
The Egrifta Tesamorelin …
-
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
26 Nov 2024 12:30 GMT
… simplified dosing for the treatment of excess abdominal fat … Drug Administration (FDA) for the F8 formulation of tesamorelin, the only medication … ;benefit of continuation of treatment in patients who have … or has had radiation treatment to their head or …